Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC0547
Trial ID NCT04811664
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment mRNA-1273|Elasomeran|Spikevax
Location approved UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
PhasePhase3
Recruitment statusCompleted
TitleA Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
Year2021
CountryUnited States
Company sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Other ID(s)VPN 3006
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: Day 1 and Day 29
Administration route intramuscular injection
Dosage Moderna COVID-19 Vaccine, 100 mcg, on Day 1 and Day 29
Pts 600
Age Adult
Outcome Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection:Measure Type: Number (95% Confidence Interval):12.2(6.1 to 21.9)|Effect of Moderna COVID-19 Vaccine on Mean Peak Nasal Viral Load:Lab:Mean (Full Range):Corteva, Target:N1:25.8(17.0 to 37.2); Lab:Corteva, Target:N2:26.3(17.3 to 38.2); Lab:UW/Northwell, Target:N1:34.4(31.3 to 37.5); Lab:UW/Northwell, Target:N2:34.1(34.1 to 34.1)|Effect of Moderna COVID-19 Vaccine on Median Peak Nasal Viral Load:Corteva, Target:Median (Inter-Quartile Range):N1:23.9(21.3 to 29.1); Lab:Corteva, Target:N2:24.3(21.9 to 29.5); Lab:UW/Northwell, Target:N1:34.4(32.9 to 35.9); Lab:UW/Northwell, Target:N2:34.1(34.1 to 34.1)
Adverse reactions No serious clinical adverse events
References PMID: 38023544
Cohort2: Day 113 and Day 141
Administration route intramuscular injection
Dosage Moderna COVID-19 Vaccine, 100 mcg, on Day 113 and Day 141
Pts 549
Age Adult
Outcome Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection:Measure Type: Number (95% Confidence Interval):31.8(20.3 to 47.2)|Effect of Moderna COVID-19 Vaccine on Mean Peak Nasal Viral Load:Lab:Mean (Full Range):Corteva, Target:N1:20.2(14.6 to 35.8); Lab:Corteva, Target:N2:20.7(15.0 to 37.0); Lab:UW/Northwell, Target:N1:28.8(18.0 to 39.1); Lab:UW/Northwell, Target:N2:30.5(21.1 to 38.6)|Effect of Moderna COVID-19 Vaccine on Median Peak Nasal Viral Load:Corteva, Target:Median (Inter-Quartile Range):N1:19.6(16.9 to 21.6); Lab:Corteva, Target:N2:20.0(17.6 to 22.1); Lab:UW/Northwell, Target:N1:29.4(22.8 to 34.6); Lab:UW/Northwell, Target:N2:31.2(24.8 to 36.3)
Adverse reactions No serious clinical adverse events
References PMID: 38023544
Cohort3: no intervention
Administration route None
Pts 311
Age Adult
Outcome Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection:Measure Type: Number (95% Confidence Interval):89.6(65.4 to 119.9)|Effect of Moderna COVID-19 Vaccine on Mean Peak Nasal Viral Load:Lab:Mean (Full Range):Corteva, Target:N1:22.3(12.8 to 37.2); Lab:Corteva, Target:N2:22.8(13.2 to 37.5); Lab:UW/Northwell, Target:N1:24.4(16.0 to 38.3); Lab:UW/Northwell, Target:N2:26.2(18.8 to 34.9)|Effect of Moderna COVID-19 Vaccine on Median Peak Nasal Viral Load:Corteva, Target:Median (Inter-Quartile Range):N1:21.0(17.3 to 25.9); Lab:Corteva, Target:N2:21.3(18.2 to 26.2); Lab:UW/Northwell, Target:N1:22.5(19.0 to 29.2); Lab:UW/Northwell, Target:N2:25.7(22.1 to 31.1)
Adverse reactions No serious clinical adverse events
References PMID: 38023544

Relationship Graph

Overview of Knowledge Graph